Knight Therapeutics Inc. (TSX:GUD)
5.69
-0.03 (-0.52%)
Apr 17, 2025, 4:00 PM EDT
Knight Therapeutics Revenue
In the year 2024, Knight Therapeutics had annual revenue of 371.30M CAD with 13.13% growth. Knight Therapeutics had revenue of 96.86M in the quarter ending December 31, 2024, with 30.55% growth.
Revenue
371.30M
Revenue Growth
+13.13%
P/S Ratio
1.53
Revenue / Employee
498.39K
Employees
745
Market Cap
566.38M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 371.30M | 43.11M | 13.13% |
Dec 31, 2023 | 328.20M | 34.64M | 11.80% |
Dec 31, 2022 | 293.56M | 50.09M | 20.57% |
Dec 31, 2021 | 243.48M | 43.96M | 22.03% |
Dec 31, 2020 | 199.52M | 152.06M | 320.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Green Thumb Industries | 1.64B |
dentalcorp Holdings | 1.55B |
Sienna Senior Living | 893.16M |
Extendicare | 1.47B |
WELL Health Technologies | 919.69M |
Cronos Group | 169.23M |
Trulieve Cannabis | 1.71B |
Curaleaf Holdings | 1.93B |
Knight Therapeutics News
- 23 days ago - Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico - Benzinga
- 4 weeks ago - Knight Therapeutics Inc. (KHTRF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Knight Therapeutics reports results - Seeking Alpha
- 4 weeks ago - Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results - GlobeNewsWire
- 5 weeks ago - Notice of Knight Therapeutics’ Fourth Quarter and Year End 2024 Results Conference Call - Financial Post
- 5 weeks ago - Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call - GlobeNewsWire
- 5 weeks ago - Knight Therapeutics to acquire Paladin Pharma for $120M - BNN Bloomberg
- 5 weeks ago - Knight Therapeutics to acquire Paladin for $120M - BNN Bloomberg